A new drug target for treatment of dyslipidaemia associated with type 2 diabetes and the metabolic syndrome?
Naoumova
Rossitza P
RP
MRC Clinical Sciences Centre, Hammersmith Hospital, London, UK
Betteridge
D John
DJ
D000091303:Angiopoietin-Like Protein 3; D000075802:Angiopoietin-like Proteins; D042682:Angiopoietins; D000818:Animals; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D006133:Growth Substances / Q000235:genetics / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000150:complications* / Q000188:drug therapy; D036341:Intercellular Signaling Peptides and Proteins; D024821:Metabolic Syndrome / Q000235:genetics; D051379:Mice; D008820:Mice, Obese; D014280:Triglycerides / Q000097:blood
D000091303:Angiopoietin-Like Protein 3; D000075802:Angiopoietin-like Proteins; D042682:Angiopoietins; C404495:Angptl3 protein, mouse; D006133:Growth Substances; D036341:Intercellular Signaling Peptides and Proteins; D014280:Triglycerides